Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
ADME
Interventions
OTHER

Controlled dietary background

Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.

OTHER

(-)-[2-14C]epicatechin intake

Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-\[2-14C\]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-\[2-14C\]epicatechin.

Trial Locations (1)

53704

Covance Clinical Pharmacology Inc., Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

collaborator

Mars, Inc.

INDUSTRY

lead

The Institutes for Pharmaceutical Discovery, LLC

INDUSTRY